We are committed to delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections. We are developing SCY-078, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, for the treatment of several serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.
A Versatile Anti-Infective
Our team strives to save and improve patients' lives. We are committed to developing and delivering innovative therapies to address difficult-to-treat and often life-threatening infections, and to transforming treatment paradigms for patients worldwide.
More About Us
Our lead candidate, SCY-078, currently in Phase 2 clinical development, is a novel and structurally distinct glucan synthase inhibitor. It is the first representative of a new triterpenoid antifungal family.
Our Science Our Pipeline
The innovation that drives our science and pipeline is a direct reflection of our leadership's passion for improving patients' lives. This leadership has a proven track record of drug development and commercialization, and deep antifungal expertise.
Leadership Board of Directors